Related Experiment Video

Updated: May 11, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Novel antibodies targeting immune regulatory checkpoints for cancer therapy

Chern Siang Lee1, Mark Cragg, Martin Glennie

  • 1Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.

British Journal of Clinical Pharmacology
|May 25, 2013
PubMed

Insights

Cancer immunotherapy advances by targeting immune regulatory checkpoints. Therapeutic antibodies, like anti-CTLA-4, are showing promise in clinical trials for treating tumors by enhancing immune system activation.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cancers develop by evading or suppressing the host immune system.
  • Understanding immune regulatory checkpoints is crucial for cancer treatment.
  • The approval of ipilumumab for melanoma highlights the potential of immunotherapy.

Purpose of the Study:

  • To review the current status of therapeutic antibodies targeting immune regulatory checkpoints.
  • To discuss novel target molecules in cancer immunotherapy.
  • To provide an overview of ongoing clinical and pre-clinical investigations.

Main Methods:

  • Review of current literature on cancer immunotherapy.
  • Analysis of clinical trial data for therapeutic antibodies.
  • Examination of pre-clinical development of novel target molecules.

Main Results:

  • Several therapeutic monoclonal antibodies targeting immune regulatory checkpoints are in clinical evaluation.
  • New target molecules are being investigated for their immunotherapeutic potential.
  • The anti-CTLA-4 antibody ipilumumab has received regulatory approval for melanoma treatment.

Conclusions:

  • Targeting immune regulatory checkpoints represents a promising strategy in cancer immunotherapy.
  • Therapeutic antibodies are a key modality in this evolving field.
  • Continued research and development are essential for advancing cancer treatment outcomes.
Keywords:
cancerimmunomodulatory antibodiesimmunotherapymonoclonal antibodies

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...